WO2001024787A1 - Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections - Google Patents

Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections Download PDF

Info

Publication number
WO2001024787A1
WO2001024787A1 PCT/SE2000/001923 SE0001923W WO0124787A1 WO 2001024787 A1 WO2001024787 A1 WO 2001024787A1 SE 0001923 W SE0001923 W SE 0001923W WO 0124787 A1 WO0124787 A1 WO 0124787A1
Authority
WO
WIPO (PCT)
Prior art keywords
immune responses
astaxanthin
mediated immune
disease
cell mediated
Prior art date
Application number
PCT/SE2000/001923
Other languages
French (fr)
Inventor
Åke Lignell
Per BÖTTIGER
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Priority to EP00970399A priority Critical patent/EP1217996A1/en
Priority to CA002388785A priority patent/CA2388785A1/en
Priority to US10/088,496 priority patent/US6773708B1/en
Priority to JP2001527786A priority patent/JP5005143B2/en
Priority to AU79788/00A priority patent/AU780797B2/en
Publication of WO2001024787A1 publication Critical patent/WO2001024787A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • xanthophylls astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections.
  • the present invention relates to the use and method of treatment concerning utilization of xanthophylls, e.g. astaxanthin, for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
  • xanthophylls e.g. astaxanthin
  • CD4 T lymphocytes can be subdivided into two major subsets - Thl cells and
  • Th2 cells These cells release different sets of cytokines that define their distinct actions in immunity.
  • Thl cells secrete interferon-gamma (IFN- ⁇ ) and are mainly involved in activating macrophages and CD8+ cytotoxic T-lymphocytes.
  • Th2 cells secrete the interleukins 11-4, 11-5 and 11-10 and are mainly involved in stimulating B cells to produce antibodies.
  • Thl cell activity may be the result of an autoimmune disease, or the result of an ongoing infection.
  • Thl cell activity diminishes when the physiological need thereof is reduced.
  • An excess activity is thus seen when the normal reduced level of Thl cell activity is not achieved as a response to the diminishing presence of the agent that induced the reaction, e.g. the starting point of an autoimmune disease.
  • Immune modulation aims at altering the balance between different subsets of responding T cells so that damaging responses are suppressed.
  • autoimmune diseases and intracellular infections are associated with the activation of Thl cells, which activate macrophages and drive an inflammatory immune response.
  • the drugs currently used to suppress the immune system can be divided into three categories:
  • Glucocorticoids influence virtually every cellular and humoral mechanism related to inflammation and immune response. However, there are also many adverse effects, including fluid retention, weight gain, diabetes, bone mineral loss and thinning of the skin.
  • Cytotoxic drugs such as azthioprine and cyclophosphamide. Cytotoxic drugs cause immunosuppression by killing dividing cells and they have serious side-effects. The use of these compounds is limited due to a range of toxic effects on tissues that have continuous cell dividing, such as the bone marrow.
  • Cyclosporin A, tacromycin and rapamycin are powerful immunosuppressive agents that interfere with T-cell signaling. All of these drugs are very broad in their action and inhibit protective functions of the immune system as well as pathological responses that cause tissue injury. Opportunistic infection is therefore a common complication of immune suppressive drugs.
  • the present invention provides a medicament for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
  • One aspect of the invention is directed to the use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
  • the excessive Thl cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections.
  • diseases that cause excessive Thl cell mediated immune responses are Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin- dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection) and HIN virus infection.
  • Xanthophylles including astaxanthin, is a large group of carotenoids containing oxygen in the molecule in addition to carbon and hydrogen.
  • the carotenoids are produced de novo by plants, fungi and some bacteria [Johnson E.A. and Schroeder W.A., 1995, Adv In Biochem Engin. Biotechn. 53: 119-178].
  • the type of xanthophyll is astaxanthin, preferably in a form esterified with fatty acids.
  • the astaxanthin is derived from a natural source, such as a culture of the algae Haematococcus sp., e.g. Haemotococcus pluvialis.
  • the medicament in the invention is preferably an oral preparation, which optionally comprises an oil of food grade and it is suitably presented in separate unit doses.
  • the medicament may comprise a mixture of different types of xanthophylls or different forms of the same xanthophyll, such as a mixture of synthetic astaxanthin and naturally produced astaxanthin.
  • the oral preparation may comprise in addition to the xanthophylls auxiliary ingredients that are pharmacologically acceptable inactive or active ingredients, such as flavoring agents, fillers, emulsifiers, etc.
  • Examples of separate unit doses are tablets, gelatin capsules and predetermined amounts of solutions, e.g. oil solutions, or emulsions, e.g. water-in- oil or oil-in-water emulsions.
  • solutions e.g. oil solutions, or emulsions, e.g. water-in- oil or oil-in-water emulsions.
  • emulsions e.g. water-in- oil or oil-in-water emulsions.
  • Another aspect of the invention is directed to a method of suppressing excessive
  • Thl cell mediated immune responses and stimulating Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient comprising administration of an Thl cell response suppressing and Th2 cell response stimulating amount of at least one type of xanthophylls to said patient.
  • Thl cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections, such as Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn ' s disease, Insulin-dependent diabetes mellitus, Tubercolosis (TB), Acute graft-versus- host disease (transplant rejection) and HIN virus infection, and the type of xanthophyll is preferably astaxanthin, particularly in a form esterified with fatty acids, e.g. from a natural source, such as a culture of the algae Haematococcus sp.
  • a natural source such as a culture of the algae Haematococcus sp.
  • the daily doses of the active ingredient of the invention will normally be in the range of 0.01 to 10 mg per kg body weight for a human calculated on the amount of astaxanthin, but the actual dose will depend on the immune response of the individual human patient, the reason for suppression of the excessive Thl cell mediated immune response, such as the type of disease causing the enhanced pathological Thl cell response, and the recommendations of the manufacturer.
  • the xanthophyll astaxanthin is commercially produced via culturing of the algae
  • Astaxanthin from other sources, and other xanthophylls as well, are expected to be similarly useful for the purposes of the invention.
  • An advantage of using astaxanthin from algae is, however, that the astaxanthin exists in a form esterified with fatty acids [ Renstr ⁇ m
  • the naturally produced astaxanthin can be obtained also from fungi and crustaceans, in addition to from algae [Johnson E.A. and Schroeder W.A., ibid].
  • Astaxin® containing 4 mg astaxanthin.
  • the daily doses recommended as an antioxidant is one capsule per day. However, 2 - 6 times that dose has been used by some patients without adverse effects. On the contrary, the higher doses have been experienced as beneficial in alleviating symptoms associated with some chronic diseases.
  • Chron's disease Patient 1 Boy, 17 years old, who had suffered from Crohn's disease for at least four years. He has been treated with anti-inflammatory agents, such as cortisone. He started to take the commercial product Astaxin ( two capsules, each containing 4 mg of astaxanthin, per day). In about two months the cortisone treatment was phased out and later on stopped altogether. The patient was asymptomatic for more than a year when he experienced a relapse. He was then received a short-term treatment with cortisone in combination with Astaxin, and the cortisone treatment was again phased out.
  • anti-inflammatory agents such as cortisone.
  • Patient 3 Man, 48 years old, who has suffered from Crohn's disease for the last 20 years. He has been operated on several times and he has been treated with cortisone. Directly after the last operation he started taking Astaxin (6 capsules per day) and no cortisone. With regard to the circumstances, he has been asymptomatic. He has compared his clinical status after the operation with the status of two other patients who were operated on at the same time and who received conventional treatment with cortisone. In comparison with these two other patients his recovery has been fully equal with theirs, with the positive exception that edema in his colon diminished more quickly than in the two other patients. Lichen ruber planus.
  • Patient 5 Male, 40 years, who suffers from psoriasis and mainly shows itself in rough skin on the elbows. After treatment with a skin cream enriched with algal meal/astaxanthin ( 100 mg astaxanthin /kg cream) twice a day for three weeks, the symptoms diminished.
  • algal meal/astaxanthin 100 mg astaxanthin /kg cream
  • Thl cell mediated diseases which are known to be Thl cell mediated diseases. Therefore it is likely that the Thl mediated response in the patients has been suppressed and that there is a shift of the Thl/Th2 balance of the immune response towards the Th2 response. Further, it is likely that patients suffering from other predominantly Thl cell mediated diseases would benefit from suppression of excessive Thl cell responses and stimulation of Th2 cell mediated immune responses during ongoing infection and/or inflammation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Th1 cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient is disclosed. Excessive Th1 cell mediated immune responses are caused by such autoimmune diseases and chronic viral and intracellular bacterial infections as Psoriasis vulgaris, Multiple sclerosis (MS), Rheumatoid arthritis, Crohn's disease, Insulin-dependent diabetes mellitus, Tuberculosis (TB), Acute graft-versus-host disease (transplant rejection) and HIV virus infection. The preferred type of xanthophyll is astaxanthin, particularly in a form esterified with fatty acids, obtainable by for example culturing the algae Haematococcus sp. Further, a method of suppressing excessive Th1 mediated immune responses and stimulating Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient is disclosed.

Description

Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections.
The present invention relates to the use and method of treatment concerning utilization of xanthophylls, e.g. astaxanthin, for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
Background of the invention.
CD4 T lymphocytes can be subdivided into two major subsets - Thl cells and
Th2 cells. These cells release different sets of cytokines that define their distinct actions in immunity. Thl cells secrete interferon-gamma (IFN-γ) and are mainly involved in activating macrophages and CD8+ cytotoxic T-lymphocytes. Th2 cells secrete the interleukins 11-4, 11-5 and 11-10 and are mainly involved in stimulating B cells to produce antibodies.
There is a balance between the activities of the Thl and Th2 cells in a normal human body. An excess of Thl cell activity may be the result of an autoimmune disease, or the result of an ongoing infection. In the normal case, the Thl cell activity diminishes when the physiological need thereof is reduced. An excess activity is thus seen when the normal reduced level of Thl cell activity is not achieved as a response to the diminishing presence of the agent that induced the reaction, e.g. the starting point of an autoimmune disease.
Immune modulation aims at altering the balance between different subsets of responding T cells so that damaging responses are suppressed. In many cases autoimmune diseases and intracellular infections are associated with the activation of Thl cells, which activate macrophages and drive an inflammatory immune response. The drugs currently used to suppress the immune system can be divided into three categories:
1) Powerful anti-inflammatory drugs of the corticosteroid family such as prednisone. Glucocorticoids influence virtually every cellular and humoral mechanism related to inflammation and immune response. However, there are also many adverse effects, including fluid retention, weight gain, diabetes, bone mineral loss and thinning of the skin.
2) Cytotoxic drugs such as azthioprine and cyclophosphamide. Cytotoxic drugs cause immunosuppression by killing dividing cells and they have serious side-effects. The use of these compounds is limited due to a range of toxic effects on tissues that have continuous cell dividing, such as the bone marrow.
3) Cyclosporin A, tacromycin and rapamycin are powerful immunosuppressive agents that interfere with T-cell signaling. All of these drugs are very broad in their action and inhibit protective functions of the immune system as well as pathological responses that cause tissue injury. Opportunistic infection is therefore a common complication of immune suppressive drugs.
It would be desirable to have an immunosuppressive agent that targets the specific part of the immune response that causes tissue injury. In particular, it would be desirable to obtain a medicament for suppression of harmful, i.e. excessive, Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient. Description of the invention The present invention provides a medicament for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
One aspect of the invention is directed to the use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
In a preferred embodiment of the invention the excessive Thl cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections. Examples of diseases that cause excessive Thl cell mediated immune responses are Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin- dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection) and HIN virus infection.
Xanthophylles, including astaxanthin, is a large group of carotenoids containing oxygen in the molecule in addition to carbon and hydrogen. The carotenoids are produced de novo by plants, fungi and some bacteria [Johnson E.A. and Schroeder W.A., 1995, Adv In Biochem Engin. Biotechn. 53: 119-178].
In a preferred embodiment of the invention, the type of xanthophyll is astaxanthin, preferably in a form esterified with fatty acids. In a particularly preferred embodiment the astaxanthin is derived from a natural source, such as a culture of the algae Haematococcus sp., e.g. Haemotococcus pluvialis. The medicament in the invention is preferably an oral preparation, which optionally comprises an oil of food grade and it is suitably presented in separate unit doses. The medicament may comprise a mixture of different types of xanthophylls or different forms of the same xanthophyll, such as a mixture of synthetic astaxanthin and naturally produced astaxanthin.
The oral preparation may comprise in addition to the xanthophylls auxiliary ingredients that are pharmacologically acceptable inactive or active ingredients, such as flavoring agents, fillers, emulsifiers, etc.
Examples of separate unit doses are tablets, gelatin capsules and predetermined amounts of solutions, e.g. oil solutions, or emulsions, e.g. water-in- oil or oil-in-water emulsions. Another aspect of the invention is directed to a method of suppressing excessive
Thl cell mediated immune responses and stimulating Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient comprising administration of an Thl cell response suppressing and Th2 cell response stimulating amount of at least one type of xanthophylls to said patient. The examples and preferred embodiments described for the use aspect of the invention also apply for this method aspect of the invention.
In particular, excessive Thl cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections, such as Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin-dependent diabetes mellitus, Tubercolosis (TB), Acute graft-versus- host disease (transplant rejection) and HIN virus infection, and the type of xanthophyll is preferably astaxanthin, particularly in a form esterified with fatty acids, e.g. from a natural source, such as a culture of the algae Haematococcus sp.
The daily doses of the active ingredient of the invention will normally be in the range of 0.01 to 10 mg per kg body weight for a human calculated on the amount of astaxanthin, but the actual dose will depend on the immune response of the individual human patient, the reason for suppression of the excessive Thl cell mediated immune response, such as the type of disease causing the enhanced pathological Thl cell response, and the recommendations of the manufacturer. The xanthophyll astaxanthin is commercially produced via culturing of the algae
Haematococcus sp. by AstaCarotene AB, Gustavsberg, Sweden. It is marketed and sold in Sweden as a dietary supplement
Astaxanthin from other sources, and other xanthophylls as well, are expected to be similarly useful for the purposes of the invention. An advantage of using astaxanthin from algae is, however, that the astaxanthin exists in a form esterified with fatty acids [ Renstrδm
B. et al, 1981, Phytochem 20(11) :2561-2564], which esterified astaxanthin thereby is more stable during handling and storage than free astaxanthin.
The naturally produced astaxanthin can be obtained also from fungi and crustaceans, in addition to from algae [Johnson E.A. and Schroeder W.A., ibid].
Case studies
During the last five years reports have been received from patients taking the commercial dietary supplement capsules of the algal meal of Haematococcus pluvialis,
Astaxin®, containing 4 mg astaxanthin. The daily doses recommended as an antioxidant is one capsule per day. However, 2 - 6 times that dose has been used by some patients without adverse effects. On the contrary, the higher doses have been experienced as beneficial in alleviating symptoms associated with some chronic diseases.
Six patient histories are disclosed more in detail below. Chron's disease Patient 1. Boy, 17 years old, who had suffered from Crohn's disease for at least four years. He has been treated with anti-inflammatory agents, such as cortisone. He started to take the commercial product Astaxin ( two capsules, each containing 4 mg of astaxanthin, per day). In about two months the cortisone treatment was phased out and later on stopped altogether. The patient was asymptomatic for more than a year when he experienced a relapse. He was then received a short-term treatment with cortisone in combination with Astaxin, and the cortisone treatment was again phased out.
Patient 2. Woman, about 50 years of age, who had suffered from Crohn's disease for a long time. She received treatment with cortisone. Now she has started to take Astaxin in parallel with her steroid medication and she reports that she feels considerably better.
Patient 3. Man, 48 years old, who has suffered from Crohn's disease for the last 20 years. He has been operated on several times and he has been treated with cortisone. Directly after the last operation he started taking Astaxin (6 capsules per day) and no cortisone. With regard to the circumstances, he has been asymptomatic. He has compared his clinical status after the operation with the status of two other patients who were operated on at the same time and who received conventional treatment with cortisone. In comparison with these two other patients his recovery has been fully equal with theirs, with the positive exception that edema in his colon diminished more quickly than in the two other patients. Lichen ruber planus.
Patient 4. Woman, more than 70 years of age, who had suffered from the disease for several years. The symptoms of the disease were inter alia open wounds which had not healed. She had been treated with anti-inflammatory agents, such as cortisone, for several years, orally and also by injection directly to the local inflammation areas. The treatment has not led to any result. She started to take 4 capsules of Astaxin per day , and after some weeks visible alleviation of the symptoms started to show up. The wounds were healed in slightly more than one month. During this period, the patient herself phased out the cortisone treatment. The dose of Astaxin was lowered to 2 capsules per day when she was asymtomatic. However, the symptoms returned in connection with a common cold. The dose was then increased to 4 capsules per day and the wounds healed again. She says herself that she now feels considerably better. Psoriasis.
Patient 5. Male, 40 years, who suffers from psoriasis and mainly shows itself in rough skin on the elbows. After treatment with a skin cream enriched with algal meal/astaxanthin ( 100 mg astaxanthin /kg cream) twice a day for three weeks, the symptoms diminished.
Patient 6. Woman, 45 years old, who suffers from psoriasis and mainly shows itself in rough skin on the elbows. After treatment with a skin cream enriched with algal meal astaxanthin ( 100 mg astaxanthin /kg cream) twice a day for three weeks, the symptoms diminished.
Thus, positive reports have been received from several patients suffering from Crohn's disease, rheumatoid arthritis, psoriasis and lichen planus. All of these diseases are autoimmune diseases which are known to be Thl cell mediated diseases. Therefore it is likely that the Thl mediated response in the patients has been suppressed and that there is a shift of the Thl/Th2 balance of the immune response towards the Th2 response. Further, it is likely that patients suffering from other predominantly Thl cell mediated diseases would benefit from suppression of excessive Thl cell responses and stimulation of Th2 cell mediated immune responses during ongoing infection and/or inflammation.

Claims

Claims
1. Use of at least one type of xanthophylls for the production of a medicament for suppression of excessive Thl cell mediated immune responses and stimulation of Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient.
2. Use according to claim 1, wherein the excessive Thl cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections.
3. Use according to claim 2, wherein the disease is Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin-dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection), or HIN virus infection.
4. Use according to any one of claims 1 -3, wherein the type of xanthophyll is astaxanthin.
5. Use according to claim 4, wherein the astaxanthin is in a form esterified with fatty acids.
6. Use according to claim 4 or 5, wherein the astaxanthin is derived from a natural source.
7. Use according to claim 6, wherein the natural source is a culture of the algae
Haematococcus sp.
8. Use according to any one of the claims 1 - 7, wherein the medicament is an oral preparation.
9. A method of suppressing excessive Thl cell mediated immune responses and stimulating Th2 cell mediated immune responses in a patient during ongoing infection and/or inflammation in said patient comprising administration of an Thl cell response suppressing and Th2 cell response stimulating amount of at least one type of xanthophylls to said patient.
10. The method according to claim 9, wherein the excessive Thl cell mediated immune responses are caused by at least one disease from the group of autoimmune diseases and chronic viral and intracellular bacterial infections.
11. The method according to claim 10, wherein the disease is Psoriasis vulgaris, Multiple sclerosis (MS), Reumatoid arthritis, Crohn's disease, Insulin-dependant diabetes mellitus, Tubercolosis (TB), Acute graft-versus-host disease (transplant rejection), or HIV virus infection.
12. The method according to claim 9, wherein the type of xanthophyll is astaxanthin.
13. The method according to claim 12, wherein the astaxanthin is in a form esterified with fatty acids.
14. The method according to claim 12 or 13, wherein the astaxanthin is derived from a natural source.
15. The method according to claim 14, wherein the natural source is a culture of the algae Haematococcus sp.
PCT/SE2000/001923 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections WO2001024787A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00970399A EP1217996A1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
CA002388785A CA2388785A1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
US10/088,496 US6773708B1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
JP2001527786A JP5005143B2 (en) 1999-10-07 2000-10-05 Use of xanthophylls such as astaxanthin for the treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
AU79788/00A AU780797B2 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903619A SE9903619D0 (en) 1999-10-07 1999-10-07 Use and method of treatment
SE9903619-6 1999-10-07

Publications (1)

Publication Number Publication Date
WO2001024787A1 true WO2001024787A1 (en) 2001-04-12

Family

ID=20417279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001923 WO2001024787A1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections

Country Status (7)

Country Link
US (1) US6773708B1 (en)
EP (1) EP1217996A1 (en)
JP (1) JP5005143B2 (en)
AU (1) AU780797B2 (en)
CA (1) CA2388785A1 (en)
SE (1) SE9903619D0 (en)
WO (1) WO2001024787A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112776A2 (en) 2003-06-23 2004-12-29 Advanced Bionutrition (Europe) Limited Inflammatory disease treatment
WO2007062274A1 (en) * 2005-11-28 2007-05-31 U.S. Nutraceuticals Llc Dba Valensa International Algal and algal extract dietary supplement composition
EP1795190A1 (en) * 2005-12-07 2007-06-13 Yamaha Hatsudoki Kabushiki Kaisha Agent for suppressing body fat accumulation
EP1800674A1 (en) * 2005-12-14 2007-06-27 Yamaha Hatsudoki Kabushiki Kaisha Agent for preventing metabolic syndrome
EP1867327A1 (en) 2006-06-16 2007-12-19 Yamaha Hatsudoki Kabushiki Kaisha Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease
WO2009052629A1 (en) * 2007-10-26 2009-04-30 Chemaphor Inc. Compositions and methods for enhancing immune response
WO2010124392A1 (en) * 2009-04-30 2010-11-04 Chemaphor Inc. Methods, compositions, and kits for the treatment of inflammatory conditions
US8211461B2 (en) 2004-09-28 2012-07-03 Chemaphor Inc. Compositions and methods for promoting weight gain and feed conversion
US10456369B2 (en) 2009-04-30 2019-10-29 Avivagen Inc. Methods and compositions for improving the health of animals
CN113749050A (en) * 2020-06-04 2021-12-07 温州医科大学 Method and system for treating type 2 diabetes mellitus by astaxanthin extract

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4933097B2 (en) * 2003-12-19 2012-05-16 株式会社メニコン Treatment and improvement of diabetes and diabetic complications
EP1719506A4 (en) * 2004-02-04 2011-01-26 Fuji Chem Ind Co Ltd Gene expression controlling agent
JP2007238441A (en) * 2004-12-03 2007-09-20 Fuji Chem Ind Co Ltd Composition for body fat reduction containing astaxanthin as active ingredient
GB0501365D0 (en) * 2005-01-21 2005-03-02 Promar As Compositions
JP2006008714A (en) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd Matrix metalloproteinase inhibitor
JP2006008718A (en) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd Cyclooxygenase activity inhibitor
JP2006008719A (en) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd Blood peroxidized-lipid inhibitor
WO2007006135A1 (en) * 2005-07-07 2007-01-18 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
JP2007254411A (en) * 2006-03-24 2007-10-04 Tokyo Univ Of Pharmacy & Life Science Aggrecanase production inhibitor
JP6580895B2 (en) * 2014-08-08 2019-09-25 株式会社コーセー Astaxanthin-containing desmoglein reducing agent
US9572783B1 (en) 2015-10-08 2017-02-21 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
EP3153160B1 (en) 2015-10-08 2021-08-11 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
IT202000032402A1 (en) * 2020-12-24 2022-06-24 Innobio S R L IMMUNOSTIMULATOR COMPOSITION TO INDUCE AN IMMUNE RESPONSE
AU2022224703A1 (en) 2021-09-28 2023-04-13 Samuel L. Shepherd Tetraterpenes for use in cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05124958A (en) * 1991-09-19 1993-05-21 Yukio Date Composition having lipidperoxide-lowering activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2619491B2 (en) * 1988-08-11 1997-06-11 サントリー株式会社 Astaxanthin-containing composition
JPH05339148A (en) * 1992-05-28 1993-12-21 T Knight Albert Substance penetrating blood-brain barrier
JPH07300421A (en) * 1994-04-28 1995-11-14 Itano Reitou Kk Anti-inflammatory agent
SE503336C2 (en) * 1994-09-19 1996-05-28 Asta Carotene Ab Means and ways of increasing poultry production
EP0806946A2 (en) * 1995-02-03 1997-11-19 Basf Aktiengesellschaft Use of carotinoids for preparing medicaments for treating dermatoses
SE522246C2 (en) * 1997-02-27 2004-01-27 Astacarotene Ab Oral preparation for prophylactic and therapeutic treatment of Helicobacter Sp. infection
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
SE511237C2 (en) * 1997-12-16 1999-08-30 Astacarotene Ab Use of at least one type of xanthophyll for the preparation of a human or veterinary drug for the prophylactic treatment of mastitis in mammalian mothers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05124958A (en) * 1991-09-19 1993-05-21 Yukio Date Composition having lipidperoxide-lowering activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMICAL ABSTRACTS [online] (COLUMBUS, OHIO, USA); 13 September 1993 (1993-09-13), DATE YUKIO ET AL.: "Lipid peroxide-lowering compositions", XP002936440, accession no. STN International Database accession no. 119:109000 *
HARUMI JYONOUCHI ET AL.: "Effects of various carotenoids on cloned, effector-stage T-helper cell activity", NUTR. CANCER, vol. 26, 1996, pages 313 - 324, XP002936441 *
SAMI T. AZAR ET AL.: "Type I (insulin-dependent) diabetes is a Th1 - and Th2-mediated autoimmune disease", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, vol. 6, no. 3, May 1999 (1999-05-01), pages 306 - 310, XP002936442 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112776A3 (en) * 2003-06-23 2005-03-31 Advanced Bionutrition Europ Lt Inflammatory disease treatment
WO2004112776A2 (en) 2003-06-23 2004-12-29 Advanced Bionutrition (Europe) Limited Inflammatory disease treatment
US8211461B2 (en) 2004-09-28 2012-07-03 Chemaphor Inc. Compositions and methods for promoting weight gain and feed conversion
KR100978877B1 (en) * 2005-11-28 2010-08-31 유.에스. 뉴트라수티칼스 엘엘씨 디비에이 발렌사 인터내셔널 Algal and algal extract dietary supplement composition
WO2007062274A1 (en) * 2005-11-28 2007-05-31 U.S. Nutraceuticals Llc Dba Valensa International Algal and algal extract dietary supplement composition
EP1795190A1 (en) * 2005-12-07 2007-06-13 Yamaha Hatsudoki Kabushiki Kaisha Agent for suppressing body fat accumulation
EP1800674A1 (en) * 2005-12-14 2007-06-27 Yamaha Hatsudoki Kabushiki Kaisha Agent for preventing metabolic syndrome
EP1867327A1 (en) 2006-06-16 2007-12-19 Yamaha Hatsudoki Kabushiki Kaisha Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease
WO2009052629A1 (en) * 2007-10-26 2009-04-30 Chemaphor Inc. Compositions and methods for enhancing immune response
US10449247B2 (en) 2007-10-26 2019-10-22 Avivagen Inc. Compositions and methods for enhancing immune response
WO2010124392A1 (en) * 2009-04-30 2010-11-04 Chemaphor Inc. Methods, compositions, and kits for the treatment of inflammatory conditions
US10456369B2 (en) 2009-04-30 2019-10-29 Avivagen Inc. Methods and compositions for improving the health of animals
CN113749050A (en) * 2020-06-04 2021-12-07 温州医科大学 Method and system for treating type 2 diabetes mellitus by astaxanthin extract

Also Published As

Publication number Publication date
EP1217996A1 (en) 2002-07-03
AU780797B2 (en) 2005-04-21
JP5005143B2 (en) 2012-08-22
US6773708B1 (en) 2004-08-10
JP2003510353A (en) 2003-03-18
CA2388785A1 (en) 2001-04-12
AU7978800A (en) 2001-05-10
SE9903619D0 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
US6773708B1 (en) Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
US4393049A (en) Treatment for obesity
JP4596734B2 (en) Treatment of statin side effects
NO327141B1 (en) The compound 9-cis retinoic acid for use in the treatment of eczema and its use in the manufacture of a medicament for the treatment of eczema.
EP1282412B1 (en) Treating irritable bowel syndrome or disease
EP0422109A1 (en) Reduction of cell proliferation and enhancement of nk-cell activity.
Carroll et al. Cholinergic reversal of manic symptoms
EA021833B1 (en) Compositions of polymeric myrcene
Vilter et al. RELATIONSHIP BETWEEN NICOTINIC ACID AND A CODEHYDROGENASE (COZYMASE): IN BLOOD OF PELLAGRINS AND NORMAL PERSONS
US20030166723A1 (en) Ige production inhibitors
WO1995017889A1 (en) Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
EP0774255B1 (en) Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
JP2012515174A (en) Composition containing fucoxanthin extract
TW200826953A (en) Agonist for healing living organisms
EP1083929A4 (en) The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20070020340A1 (en) Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
EP0087865A2 (en) Pharmaceutical composition
SG192527A1 (en) Composition useful for the prevention or reduction of the progression of prostate cancer
CA2346647C (en) Treatment of dyspepsia
WO2020062780A1 (en) Medicament for preventing and treating ischemic heart diseases or ischemic encephalopathy or thrombosis and use thereof
CN113521050B (en) Compositions containing cannabidiol and their use in treating systemic inflammatory response syndrome
JP2003024010A (en) Function-enhancing supplementary food comprising as main ingredient green tea catechin
RU2310463C1 (en) Hepatoprotective probiotic agent
CN111655250A (en) Composition for preventing or improving nociceptive pain
CN108904807A (en) Melbine complex composition and its application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2388785

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10088496

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000970399

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 527786

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 79788/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000970399

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 79788/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000970399

Country of ref document: EP